Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up

Abstract Background and Aims During long-term follow-up kidney donors are at increased risk of hypertension and end-stage renal disease after donation. Hypertension is a known risk factor for development of cardiovascular disease, but it is unknown whether kidney donors are at increased risk of cardiovascular disease. We evaluated a large Norwegian kidney donor cohort and assessed prevalence of ischemic heart disease after donation compared to healthy controls. Prevalence of cancer, diabetes and cerebrovascular disease was also calculated. Method Follow-up data were retrospectively retrieved from past kidney donors. Healthy non-donor controls from a general population screening study were selected. Controls were selected according to standard donation criteria, assessed in similar time periods as the living donors. Stratified logistic regression was used to estimate associations with various disease outcomes. The diagnoses at follow-up were self-reported for the controls and registered by a physician for the donors. A total of 1029 donors and 16084 controls were included. Results Mean observation time was eleven years after donation. Forty-four per cent of donors were male and mean age at follow-up was 56 years. Among the controls, 39 % were male and mean age at follow-up was 53 years. At the time of follow up, 3.5 % of donors vs 1.7 % of controls had been diagnosed with ischemic heart disease, 3.7 % vs 4.4 % cancer, 1.8 % vs 1.4 % cerebrovascular disease and 4.1 % vs 1.9 % diabetes. After adjusting for gender, age at follow up, smoking at baseline, BMI at baseline, systolic blood pressure at baseline and time since donation (time since participation in general population survey for controls), odds ratio for ischemic heart disease was 1.64 (CI 1.10-2.43; P=0.01) in previous kidney donors compared with healthy controls. Other outcomes did not differ significantly between donors and controls. Conclusion During long-term follow-up of kidney donors we find an increased risk of ischemic heart disease compared to healthy controls. This information may be important in the follow-up and selection process of living kidney donors.

Download Full-text

Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: Long-term follow-up of the HUNT 1 study

Atherosclerosis ◽

10.1016/j.atherosclerosis.2010.06.008 ◽

2010 ◽

Vol 212 (2) ◽

pp. 614-620 ◽

Cited By ~ 17

Author(s):

Inga Thorsen Vengen ◽

Ane Cecilie Dale ◽

Rune Wiseth ◽

Kristian Midthjell ◽

Vibeke Videm

Keyword(s):

Diabetes Mellitus ◽

Heart Disease ◽

Ischemic Heart Disease ◽

Diabetes Mellitus Type 2 ◽

Diabetes Mellitus Type ◽

Ischemic Heart ◽

Long Term Follow Up

Download Full-text

Self-reported physical activity predicts long-term coronary heart disease and all-cause mortalities. Twenty-one-year follow-up of the Israeli Ischemic Heart Disease Study

Archives of Family Medicine ◽

10.1001/archfami.4.4.323 ◽

1995 ◽

Vol 4 (4) ◽

pp. 323-329 ◽

Cited By ~ 44

Author(s):

C. B. Eaton

Keyword(s):

Physical Activity ◽

Coronary Heart Disease ◽

Heart Disease ◽

Ischemic Heart Disease ◽

Ischemic Heart ◽

One Year ◽

Disease Study

Download Full-text

Low mortality from lymphocyte predominant hodgkin's disease with long-term follow-up

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(94)90824-9 ◽

1994 ◽

Vol 30 ◽

pp. 268-269

Author(s):

Stephan Bodis ◽

Madeleine Kraus ◽

Geraldine Pinkus ◽

Barbara Silver ◽

Peter Mauch

Keyword(s):

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Long Term Follow Up

Download Full-text

Long-Term Follow-up of Residual Mediastinal Masses in Treated Hodgkin's Disease Using MR Imaging

Acta Radiologica ◽

10.1177/02841851960371p168 ◽

1996 ◽

Vol 37 (1P1) ◽

pp. 323-326 ◽

Cited By ~ 5

Author(s):

R. Nyman ◽

G. Forsgren ◽

B. Glimelius

Keyword(s):

Mr Imaging ◽

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Mediastinal Masses ◽

Long Term Follow Up ◽

Residual Masses ◽

The Masses ◽

Post Therapy

Purpose: Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Material and Methods: Ten patients, with substantial residual mediastinal masses of low signal intensity (SI) in the T2-weighted image (T2WI), were reinvestigated with MR 19–79 months after completing treatment of Hodgkin's disease. All patients were in complete remission. Results: During the follow-up period, the masses had decreased in size by 0–95% (median 67%) as compared to their initial post-therapy size. The SI continued to be low in the T2WI and was unaffected by the degree of size reduction. Conclusion: It is speculated that these mainly fibrotic residual masses undergo slow degradation of the fibrotic part and/or resorption of remaining inflammatory tissue. It is important to understand the natural, long-term MR imaging changes of these residual masses in order more easily to recognize tumour recurrence or other pathologic conditions.

Download Full-text

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.

Journal of Clinical Oncology ◽

10.1200/jco.1983.1.7.432 ◽

1983 ◽

Vol 1 (7) ◽

pp. 432-439 ◽

Cited By ~ 36

Author(s):

N Tannir ◽

F Hagemeister ◽

W Velasquez ◽

F Cabanillas

Keyword(s):

Complete Remission ◽

Median Survival ◽

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Survival Curve ◽

Salvage Chemotherapy ◽

Significant Prognostic Factor ◽

Long Term Follow Up

Thirty-six consecutive patients with advanced recurrent Hodgkin's disease resistant to chemotherapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) were treated with doxorubicin (Adriamycin), bleomycin, (dacarbazine) DTIC, (lomustine) CCNU, and prednisone (ABDIC). Among the 34 patients evaluable for response, complete remission occurred in 35% and partial remission in 35%. The achievement of complete remission during primary MOPP induction was a statistically significant prognostic factor that predicted complete remission with ABDIC (p less than 0.01). The median time to complete remission was 2 months (range 1-11 mo). The median relapse-free survival time for complete responders is 47 months, and an estimated 53% of all patients who achieve complete remission are projected to be alive, free of disease off therapy at 3 years from initiation of ABDIC. The median survival of all patients is 24 months. The median survival of complete responders, partial responders, and nonresponders is 70, 17, and 4 months, respectively. The survival curve for complete responders is significantly different from that for partial responders (p less than 0.01); the survival curve for partial responders is also significantly different from that of nonresponders (p less than 0.01). Toxicity of ABDIC was acceptable; only one patient died from complications of myelosuppression. Our results indicate that ABDIC is a potentially curative regimen for a fraction of patients with MOPP-resistant Hodgkin's disease who achieve complete remission with prior MOPP therapy. It also prolongs the survival of patients who do not achieve complete remission with prior MOPP therapy.

Download Full-text